$PMCB Cashflow Statement | Understand Stock

$PMCB

$0.33 -$0.01 (2.45%) Close

$PMCB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2026 12 months to Apr 30, 2026	FY2025 12 months to Apr 30, 2025	FY2024 12 months to Apr 30, 2024	FY2023 12 months to Apr 30, 2023	FY2022 12 months to Apr 30, 2022
Cash flows from operating activities:
Net Income (Loss)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on forgiveness of Paycheck Protection Program loan
Other non-cash expenses
Gain on related party investment - TNF
Gain on related party investment - QCLS
Issuance costs – Series C preferred stock and warrants
Loss on issuance of Series C preferred stock
Gain on re-fair value of warrants
Non-cash interest income
Non-cash warrant liability
Intangible asset impairment
Loss on long term asset
Other non-cash income
Stock issued for services
Stock issued for compensation - RSUs
Stock-based compensation
Stock-based compensation - options
Unrealized (gain) loss on marketable equity securities
Change in fair value of warrant liability
Change in fair value of derivative liability
Change in fair value of convertible note receivable - Femasys
Change in fair value of warrant assets - Femasys
Change in fair value of investment - TNF
Change in fair value of warrants - TNF
Change in fair value of investment - QCLS
Change in fair value of warrants - QCLS
(Increase) decrease in prepaid expenses and other current assets
Decrease in other assets
Decrease in accrued expenses
Increase (decrease) in accounts payable
Increase (decrease) in accrued expenses
Net cash used in operating activities
Investment in preferred stock and warrants
Investment – convertible note receivable and warrants
Investment in preferred stock and warrants - QCLS
Proceeds from investment – note receivable
Net cash provided by (used in) investing activities
Payment of insurance financing loan
Repurchase of common stock, net
Net proceeds from issuance of Series C preferred stock
Redemption of preferred stock
Payment of Series C convertible preferred stock dividends
Net proceeds from warrant exercise
Proceeds from sale of common stock, net of issuance costs
Net cash provided by (used in) financing activities
Effect of currency rate exchange on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of the year
Cash and cash equivalents at end of the year
Supplemental disclosure of cash flows information:
Cash paid during the year for income taxes
Cash paid during the years for interest expense
Non-cash equity issuance costs

Supplemental schedule of non-cash investing and financing activities:
Accrual of Series C Convertible Preferred Stock dividends
Accretion of discounts to redemption value of Series C Preferred Stock
Initial fair value of investment in QCLS Series H preferred shares
Initial fair value of investment in QCLS Series H warrants
Non-cash derivative liability at initial fair value
Non-cash warrant liability at initial fair value
Reclassification of Series B Convertible Preferred Stock and dividends to current liability
Accrued Series B Convertible Preferred Stock dividends
Non-cash conversion of Series C convertible stock
Change in fair value associated warrant exercises
Fair value of contingently redeemable placement agent warrants
Series B Convertible Preferred Stock dividends
Accretion of discounts to redemption value of Series B Preferred Stock
Accretion of discounts to redemption value of Series B Convertible Preferred Stock
Excise tax accrued on repurchase of common stock

Comments